{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Lyell Immunopharma, Inc."},"Symbol":{"label":"Symbol","value":"LYEL"},"Address":{"label":"Address","value":"201 HASKINS WAY,SUITE 301, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 695-0677"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors)."},"CompanyUrl":{"label":"Company Url","value":"https://www.lyell.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Gary Lee","title":"Chief Scientific Officer"},{"name":"Lynn Seely","title":"President, Chief Executive Officer & Director"},{"name":"Richard D. Goold","title":"Chief Information Officer"},{"name":"Stephen Hill","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}